New Research Confirms Castle Biosciences’ DecisionDx-Melanoma Test’s Ability to ID Patients Who Can Safely Forgo SLNB
Two new studies confirm that Castle’s DecisionDx-Melanoma test can accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity who can safely consider forgoing the sentinel lymph node biopsy.